A review of existing data on nitroimidazoles as part of efforts to find new drugs to treat human African trypanosomiasis revealed the possible suitability of fexinidazole, which had been in preclinical development by Hoechst in the 1980s as a broad-spectrum antiprotozoal agent but not developed further; it was studied further by DNDi. Information is provided about its pharmacokinetics, efficacy, safety and clinical development.
Presentation from ‘Progress Made and Challenges Ahead in Clinical Research and Development of New Treatments for Human African Trypanosomiasis’. Symposium from International Scientific Council for Trypanosomiasis Research and Control (ISCTRC) Meeting - Kampala, Uganda, 22 September 2009.
Recent progress in discovering new drugs: fexinidazole and other candidates in the pipeline.